drug
Maxtrex
Marketedupdated 5mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval40 co-mentions · 13 sources
- drugMethotrexate Teva39 co-mentions · 18 sources
- drugMethotrexate Intas39 co-mentions · 18 sources
- drugMETHOTREXATE39 co-mentions · 18 sources
- drugMETHOTREXATE SODIUM32 co-mentions · 11 sources
- tagOncology4 co-mentions · 2 sources
- tagDrug Shortage3 co-mentions · 3 sources
- tagAML1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 79 investigational indications.
indications
investigational
Breast CancerDLBCLRheumatoid ArthritisPsoriasis
all catalysts(8)
approval · 6
Aug 24, 2020
approval
METHOTREXATE — FDA approval
Maxtrex
→
Mar 10, 2022
approval
METHOTREXATE — FDA approval
Maxtrex
→
Sep 12, 2024
approval
METHOTREXATE — FDA approval
Maxtrex
→
May 29, 2025
approval
METHOTREXATE — FDA approval
Maxtrex
→
Mar 13, 2026
approval
METHOTREXATE — FDA approval
Maxtrex
→
Apr 15, 2026
approval
METHOTREXATE SODIUM — FDA approval
Maxtrex
→
phase 1 2 completion · 1
Trials studying Maxtrex
- phase2A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
- phase4A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
- phase2A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- phase3A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
- phase2Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- phase2A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- phase1Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- phase2Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 10, 2029
~2.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (139)
- Oct 28, 2035formulationUS 11129833
- Oct 29, 2034formulationUS 11771701
- Jan 2, 2033method-of-use (U-1349)US 10231927
- Jan 2, 2033formulationUS 10610485
- Jan 2, 2033method-of-use (U-1699)US 11116724
- Jan 2, 2033formulationUS 11969503
- Jan 2, 2033formulationUS 12396947
- Jan 2, 2033formulationUS 9259427
- Jan 2, 2033formulationUS 9855215
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- May 27, 2031formulationUS 88148344.6y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 114977533.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 123576423.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 84806313.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 85798653.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 89450633.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Mar 19, 2030formulationUS 94213333.5y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Jun 1, 2029method-of-use (U-1442)US 86642312.7y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 107098442.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 116847232.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Mar 10, 2029formulationUS 98679492.4y
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Oct 4, 2026formulationUS 8021335
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 11446441
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 8562564
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9533102
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
- Jan 24, 2026formulationUS 9629959
News(2)
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.fiercebiotech · 2mo ago
- Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeRestricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.stat · 4mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that